Showing posts with label gene therapy. Show all posts
Showing posts with label gene therapy. Show all posts





A step forward in gene therapy may mark further benefits for those suffering from Type 1 Diabetes.


By applying gene therapy to dogs for up to four years, minus the effects of hypoglycaemia, the advance could prove advantageous for diabetics. The change from using the methods on mice and using dogs (namely Beagles) instead has shown positive success.


“Moving from mice to large animals is a big step,” said Dr. Fatima Bosch, Director of the Center of Animal Biotechnology and Gene Therapy. “If something works well in large animals, we have reason to believe, based on the previous experience in the field of gene transfer, that it is likely that we will see a similar outcomes in humans. For example, gene therapy that worked well in large animals to treat haemophilia is now seeing positive results in clinical trials with humans. We hope that in a few years, we’ll be able to test this therapy for type 1 diabetes in humans as well.”


The dogs were given insulin and glucokinase through an adenoassociated virus (AAV) vector – a vehicle which transports DNA using a virus that is not designed to harm its host. It can still “infect” them, but the cargo could contain whatever the creator wishes. In this case, the insulin and glocokinase is the cargo, which is beneficial.




Insulin is a very familiar component for those suffering from either type of diabetes, which helps to regulate the glucose in the blood. Whilst naturally created by the pancreas, those suffering from diabetes go through the issue that the pancreas produces too little, meaning that the body’s blood sugar is not regulated properly. Through injections and (or) a healthy diet, this is often maintained quite well. Glucokinase is partnered to insulin, which also helps to regulate the rise and fall of circulating glucose levels.


By injecting them into the dogs, researchers found that the dogs maintained normal blood glucose levels for up to four years without any signs of hypoglycaemia and without any need of further injections.


With further testing proving to be promising, the researchers hope to be able to test on humans in the future.







Type 1 Diabetes – Treatable with Gene Therapy?

heart vessels10 years ago, patients whose wellness was affected by severe heart disease were injected with adenovirus encoding angiogenic growth factor, or AdVEGF121. Now, a decade later, they’re doing just as well, if not better, than patients treated with traditional medical therapy. The secret? They’ve grown new blood vessels.


The gene therapy clinical trial and review took place at Weill Cornell Medical College, and was published in the journal Human Gene Therapy. 31 patients took part in the trial, and their wellbeing depended on the results, as they were not candidates for coronary artery bypass surgery (CABG). These patients had severe blockages of the blood vessels that supply the heart, and so their heart was directly injected with the gene therapy.


The researchers reported their findings alongside doctors at Baylor College of Medicine and Stony Brook University Medical Centre.  According to a press release from co-senior author Dr Todd Rosengart, professor and chair of the Michael E. DeBakey Department of Surgery at Baylor College of Medicine, formerly of Stony Brook University Medical Centre, ‘We only had an idea of what the outcome might be based on promising studies in the lab, so there was concern, but those who received this treatment really had no other treatment options.’


The goal of coronary artery bypass surgery is to improve heart health by redirecting blood flow to the heart, and so this wasn’t an option for the patients in this study, who had severe blood vessel disease. However, ten years on, the researchers say they have evidence that the gene therapy works by helping to repair damaged blood vessels, and the results open the door for larger clinical trials.


Of the two groups involved in the study, the first only received the gene therapy whilst group B also received conventional coronary artery bypass grafting. The survival rate for the latter group was 31%, whereas this rose to a 40% ten-year survival rate for group A. Rosengart commented, ‘While there were health issues that needed additional treatments, such as cardiac revascularization and implantable cardioverter-defibrillators among both groups, overall this group of individuals had an outcome greater than what we believe they would have if they had not received the gene therapy.’


The authors added that there were no negative side effects from the therapy, which was a concern at the beginning of the study. With that in mind, and with the promising results of the 10-year trial, researchers at Weill Cornell Medical College, Weill Cornell Medical College-Qatar and Baylor College of Medicine are now planning new clinical trials.



Could Heart Disease Patients Grow New Blood Vessels?

Is a Contraceptive Injection the Right Choice for YouThanks to a potent new gene therapy technique, scientists are claiming that you can end your misery of arthritis pain and protect your joints from life-long wear and tear, using only a single injection. According to wellness experts, this is a ground-breaking treatment which could improve the wellbeing of millions of Britons, who are crippled by the debilitating disease.


The therapy is a major breakthrough because it not only stops the destruction of your joint, but it also appears to protect it against damage. Current treatments can only relieve the symptoms of osteoarthritis, but this new wonder-jab can be given to people at risk of developing the disease years in advance of it striking. Expensive joint replacement operations, which cost the NHS £1billion a year, are the only cure for arthritis at present.


Arthritis affects 10 million people in Britain, with osteoarthritis accounting for at least 8.5million cases. This subset of the disease causes your bones to rub against each other as your cartilage breaks down, which triggers pain in your hands, spine, knees and hips. Rheumatoid arthritis, on the other hand, occurs when your immune system attacks the joints, and is more severe but less common, affecting almost 700,000 people.


Now, a new study has found a protein which acts as a lubricant between the bones in your joint, protecting against osteoarthritis and blocking the loss of cartilage. One injection of the gene that makes this protein has been shown to prevent knees from developing age- and injury-related osteoarthritis, and could relieve pain and other symptoms of arthritis. Whilst it’s not currently possible for gene therapy to regenerate cartilage that you have already lost, the researchers claim that one day it could prevent or delay the onset of the disease.


The study was published in the journal Science Translational Medicine by researchers from the Baylor College of Medicine in Houston, Texas. They found that, in mice, a naturally-occurring protein called lubricin – or Proteoglycans 4 – protected against osteoarthritis. Dr Brendan Lee, professor of molecular and human genetics, commented, ‘The lubricin protein was expressed for the life of the mouse after a single injection into the joint.’


According to Professor Alan Silman, medical director of Arthritis Research UK, ‘There are some indications that gene therapies could lead to new treatments for the millions of people living with the pain caused by osteoarthritis. Further research is now needed to see if these findings in mice could be translated into an effective treatment for humans.’



Could Single Jab End a Lifetime of Arthritic Wear and Tear?

gene arthritisGene therapy could offer a breakthrough in the treatment of rheumatoid arthritis. The healthy cells of patients in a German study were injected into joints inflamed by the condition to help them heal.


The success of that process has now paved the way for further, bigger studies that might finally provide a breakthrough in treatment for rheumatoid arthritis and potentially even a cure.


Rheumatoid arthritis is an autoimmune disorder in which the body’s immune system turns on itself. It causes inflammation in the joints, typically the ankles, knees, wrists and elbows but also affecting the neck and shoulders, too. The condition is a debilitating one, which is treated by a combination of anti-inflammatory medication and over-the-counter pain relief.


Gene therapy involves modifying the genes inside cells to repair a genetic defect or to trigger the production of proteins that can stop the disease’s progression. The first gene therapy was pioneered in 1990 and advances in the technique have offered hope to sufferers of many conditions.


The German research into rheumatoid arthritis was carried out in 1997 and 1998 in Dusseldorf and its results published in the journal Human Gene Therapy. The original study involved six patients but eventually only two female patients, both aged under 75 and suffering from rheumatoid arthritis, took part in the gene transfer.


The medics injected genetically modified cells that had been taken from each patient’s own body into a joint affected by the disease to stimulate production of the protein human interleukin-1 receptor antagonist. This works to stop cartilage breaking down and becoming inflamed. Over time the injected cells keep working to reduce inflammation and alleviate the joint pain, with the patients confirming they had reduced pain and swelling four weeks after the injection.


The results of the study demonstrate that gene therapy can successfully treat and offer relief from the symptoms of rheumatoid arthritis, providing great hope for those suffering from the debilitating disease.



Rheumatoid Arthritis Could Be Treated with Gene Therapy